Figure 4.

Simvastatin minimally enhances response to PD-1 ICB in a small subset of TC-1-bearing mice in vivo. TC-1 cells were injected into the right flank, and animals were randomized on day 7 to treatment with simvastatin (60 mg/kg/day by oral gavage), anti-PD-1 (200 µg IP two times per week), statin+anti-PD-1, or statin+anti-PD-1 + anti-CD8 (200 µg IP two times per week) for 2 weeks. (A) Schema of experiment. (B) Tumor growth curves showing mean±SEM. (C) Tumor growth curves showing individual animals, compared with control. (D) Kaplan-Meier survival curves. n=5 animals per group. ICB, immune checkpoint blockade.